Lin Lin

Lin Lin

Auto-generated profile, based on publicly available information

Lin Lin

Cardiovascular center, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2013 in Leukemia
Verified
Journal Article
Closed access
HHHsin-An Hou
Hsin-An Hou
CLC-C Lin
C-C Lin
WCWen-Chien Chou
Wen-Chien Chou
CLC-Y Liu
C-Y Liu
CCC-Y Chen
C-Y Chen
HTH-F Tien
H-F Tien

17 July 2013 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
CHChi-Lun Huang
Chi-Lun Huang
YWYen-Wen Wu
Yen-Wen Wu
CWChih-Cheng Wu
Chih-Cheng Wu
LLLin Lin
Lin Lin
YWYu-Chin Wu
Yu-Chin Wu
WYWei-Shiung Yang
Wei-Shiung Yang
Background: Adipokines, including adipocyte fatty acid-binding protein (A-FABP), have been demonstrated to be involved in the pathogenesis of atherosclerosis. In the present study, we investigated the association of circulating A-FABP level with severity of myocardial perfusion abnormalities analyzed by Tl-201 dipyridamole single-photon emission computed tomography. Methods: A total of 170 patients with coronary artery disease (CAD) from cardiovascular clinics were enrolled in the study. Serum A-FABP levels, echocardiography, and stress myocardial perfusion imaging results were analyzed. Results: Compared with the patients with mild CAD (summed stress score [SSS] ≤ 8), those with moderate to severe CAD (SSS > 8) had significantly higher A-FABP concentrations. However, the difference was attenuated in the subgroup of patients with heart failure. In the correlation analyses, A-FABP level was correlated with age, body mass index, waist circumference, levels of creatinine, fasting glucose, high-sensitivity C-reactive protein, N-terminal pro-brain natriuretic peptide, adiponectin, and several echocardiographic parameters, including left ventricular ejection fraction. Multivariate logistic regression analysis demonstrated that the A-FABP level was not only associated with higher SSS (odds ratio, 1.30; 95% confidence interval [CI], 1.01–1.69; P = 0.048), but also an independent risk factor for heart failure (odds ratio 2.71, 95% CI, 1.23–5.94; P = 0.013). Conclusions: Serum A-FABP levels not only were associated with myocardial perfusion abnormalities and left ventricular function, but also predicted the presence of heart failure in our patients with CAD.

1 June 2020 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MLMin-Tsun Liao
Min-Tsun Liao
CLCheng-Pin Lee
Cheng-Pin Lee
TLTing-Tse Lin
Ting-Tse Lin
CJChien-Boon Jong
Chien-Boon Jong
TCTsung-Yan Chen
Tsung-Yan Chen
CWChih-Cheng Wu
Chih-Cheng Wu

1 December 2019 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
WHWei-Chun Huang
Wei-Chun Huang
CHChih-Hsin Hsu
Chih-Hsin Hsu
SSShih-Hsien Sung
Shih-Hsien Sung
WHWan-Jing Ho
Wan-Jing Ho
CCChun-Yuan Chu
Chun-Yuan Chu
SCShu-Meng Cheng
Shu-Meng Cheng
Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

1 April 2018 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MHMu-Yang Hsieh
Mu-Yang Hsieh
LLLin Lin
Lin Lin
TCTsung-Yan Chen
Tsung-Yan Chen
DCDao-Ming Chen
Dao-Ming Chen
MLMing-Hsien Lee
Ming-Hsien Lee
KHKuan-Yu Hung
Kuan-Yu Hung

26 October 2016 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
CWChih-Cheng Wu
Chih-Cheng Wu
TCTsung-Yan Chen
Tsung-Yan Chen
MHMu-Yang Hsieh
Mu-Yang Hsieh
LLLin Lin
Lin Lin
WYwei chung Yang
wei chung Yang
DTDer-Cherng Tarng
Der-Cherng Tarng
Background and objectives: Inflammation is relevant in restenosis of atherosclerotic vascular diseases, but its role in dialysis arteriovenous fistula remains unknown. In animal studies, upregulation of monocyte chemoattractant protein-1 has been shown in venous segments of arteriovenous fistula. We, therefore, aimed to investigate serial changes in circulating monocyte chemoattractant protein-1 after percutaneous transluminal angioplasty of dialysis arteriovenous fistulas and its relation to restenosis. Design, setting, participants, & measurements: Fifty-nine patients with dysfunctional arteriovenous fistulas that were referred for percutaneous transluminal angioplasty were enrolled prospectively between January of 2010 and July of 2012. Three of them were excluded due to percutaneous transluminal angioplasty failure or acute infection. Blood was sampled from arteriovenous fistulas at baseline, 2 days, 2 weeks, and 3 months after percutaneous transluminal angioplasty. Clinical follow-up was continued monthly for 3 months. Angiographic follow-up was arranged at the end of 3 months. Seventeen patients without significant stenosis were enrolled as the control group. Results: Fifty-six patients completed clinical follow-up. Significant increases in monocyte chemoattractant protein-1 were observed at 2 days and 2 weeks (both P<0.001) after percutaneous transluminal angioplasty. Twenty-three (41%) patients had symptomatic restenosis. The restenosis group had a higher percentage change in monocyte chemoattractant protein-1 levels at 2 days (median =47%; interquartile range, 27%–65% versus median =17%; interquartile range, 10%–25%; P<0.001) after percutaneous transluminal angioplasty compared with the patent group. Fifty-two patients completed angiographic follow-up. A positive correlation between relative luminal loss and monocyte chemoattractant protein-1 increase at 2 days after percutaneous transluminal angioplasty was found (r=0.53; P25% postangioplasty increase of monocyte chemoattractant protein-1 was significantly associated with restenosis after percutaneous transluminal angioplasty (hazard ratio, 5.36; 95% confidence interval, 1.81 to 15.8). Conclusions: Circulating monocyte chemoattractant protein-1 levels were elevated 2 days and 2 weeks after percutaneous transluminal angioplasty. Early postangioplasty increase of monocyte chemoattractant protein-1 level was associated with restenosis of arteriovenous fistulas.